CSE: AIAI | OTCQB: AINMF | FRA: 8TV

Investor Presentation

Press Releases

September 15, 2023 – NetraMark Private Placement – Press Release Clarification

September 11, 2023 – NetraMark Announces Private Placement Financing

July 19, 2023 – Pharmaceutical Industry Veteran Joins NetraMark Advisory Board

July 5, 2023 – NetraMark Announces Shares for Debt Settlement  

June 22, 2023 – NetraMark Enters into Advisor Agreement 

June 21, 2023 – NetraMark Announces Engagement of ARU Global Inc.

June 14, 2023 – NetraMark Closes Second and Final Tranche of Private Placement

June 9, 2023 – NetraMark Closes First Tranche of Private Placement

June 7, 2023 – NetraMark Announces Uplist to the OTCQB Market

June 6, 2023 – NetraMark Announces Increase to Private Placement Financing

June 1, 2023 – NetraMark Announces Private Placement Financing

June 1, 2023 – NetraMark to Attend American Society of Clinical Oncology Conference in Chicago

May 30, 2023 – NetraMark to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Wednesday, May 31 and Wednesday June 7, 2023

May 16, 2023 – NetraMark, the First Public AI Company to Launch Clinical Trial De-Risking Technology that Integrates ChatGPT

May 9, 2023 – NetraMark engages ITG as Market Maker to enhance liquidity

May 5, 2023 – NetraMark retains Renmark Financial Communications Inc.

May 2, 2023 – NetraMark Successfully Delivers on Biopharma Client Contract

March 24, 2023 – NetraMark Announces Closing of Private Placement

March 21, 2023 – Healthcare Strategy Leader Joins NetraMark Advisory Board

March 15, 2023 – NetraMark Uncovers Unique Alzheimer’s Disease Subtypes

February 27, 2023 – NetraMark Releases Paper Demonstrating AI Capabilities to Derive Insights Using Clinical Scale Data

January 30, 2023 – Introducing NetraMark – A Pharma AI Company

Financial Releases

Sedar & Financial Reports

Corporate Documents

MNP LLP

[Auditors]

111 Richmond St. W Suite 300
Toronto, ON M5H 2G4

416.596.1711

Odyssey Trust

[Transfer Agent]

United Kingdom Building 323
409 Granville Street
Vancouver, BC V6C 1T2

1.833.392.7716

Corporate Directory

NetraMark

[Head Office]

1655 Dupont St. #Suite 101
Toronto, ON M6P 3S9

investors@nurosene.com

Fasken Martineau DuMoulin LLP

[Legal]

2400 – 333 Bay St.
Toronto, ON M5H 2T6

416.366.8381

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.